Advertisement

Topics

Latest "Cazenove Group Limited" News Stories

02:15 EDT 21st July 2018 | BioPortfolio

Here are the most relevant search results for "Cazenove Group Limited" found in our extensive news archives from over 250 global news sources.

More Information about Cazenove Group Limited on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Cazenove Group Limited for you to read. Along with our medical data and news we also list Cazenove Group Limited Clinical Trials, which are updated daily. BioPortfolio also has a large database of Cazenove Group Limited Companies for you to search.

Showing "Cazenove Group Limited" News Articles 1–25 of 10,000+

Relevant

JPMorgan Cazenove provides wrong medicine for Shire, downgrading its rating to ‘neutral’

JPMorgan's analysts said: “Valuation remains undemanding, but with few 2018 or 2019 catalysts beyond a potential NeuroScience spin, which we do not see creating fundamental value, we struggle to see outperformance this year”


FTSE 250 movers: Capita jumps on JPM upgrade; Grainger hit by downgrade

London's FTSE 250 index was down 0.3% to 20,953.24, with broker notes providing much of the action. Outsourcer Capita was the best performer as JPMorgan Cazenove upgraded the stock to 'overweight' ...

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today. Following the recent announcement of positive field trial data in a European field trial, the Company met earlier today with investors and analysts at NASDAQ’...


Genetic Technologies Limited: Update on Strategic Alliance

MELBOURNE, Australia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”, “GTG”), wishes to advise that the Company is presently in discussions with the ASX regarding the possible application of ASX Listing Rule 11.1; its structure / operations in compliance with ASX Listing Rule 12.5 and whether a strategic alliance with Blockchain Globa...

Quotient Limited to Host Investor Day on July 16, 2018

JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July 16, 2018 from 9:00am – 1:00pm ET, in New York, NY. At the event, Franz Walt, Chief Executive Officer of Quotient Limited, along with other members of the management team, will provide a briefing on ...

Genetic Technologies Limited: Project Shivom Strategic Alliance

MELBOURNE, Australia, March 06, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG)  (NASDAQ:GENE) (“Company”, “GTG”) a diversified molecular diagnostics company; provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic (non-hereditary) breast cancer, embracing blockchain technologies across genomic testing platforms, is pleased...

Quotient Limited Announces Appointment of Franz Walt as Non-Executive Director

JERSEY, Channel Islands, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt to its board of directors effective February 19, 2018 Mr. Walt joins Quotient’s board of directors with over 29 years of experience in leadership roles at two of the largest, most influential healthcare compan...

Quotient Limited Announces Completion of Senior Secured Notes Offering

JERSEY, Channel Islands, July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023 (the “Notes”). On June 29, 2018, the Company, completed the second and final closing (the “Second Closing”) of...

Quotient Limited appoints Franz Walt as Chief Executive Officer

JERSEY, Channel Islands, May 29, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt, as its Chief Executive Officer. Mr Walt who retired earlier this year as the President of Siemens Healthineers, Laboratory Diagnostics, is a member of Quotient's Board of Directors, and had been appointed as the interim ...

Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma

SYDNEY, Australia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) announced today that it has received a milestone payment from the Company’s Chinese partner for eftilagimod alpha (IMP321), EOC Pharma, an oncology focused affiliate of Eddingpharm. The milestone payment of US$1 million relates to the clinical development of eftilagimod alpha in China and follows ...

Quotient Limited Reports Commencement of EU Blood Grouping Field Trial

JERSEY, Channel Islands, May 17, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validation (V&V) phase for its initial blood grouping MosaiQ™ microarray (IH I) and has commenced its European field trials. “I am very pleased to announce the start of our European field trials for...

Quotient Limited to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference

JERSEY, Channel Islands, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14th, 2018 at 1:30 p.m. EST at the Lotte New York Palace Hotel, in New York, NY...

Quotient Limited Reports Concordance Data from the MosaiQ European Field Trial

Field trial concordance data exceed targeted criteriaPlanned issuance of $36 million in Senior Secured Notes JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported concordance data for the initial MosaiQ blood grouping microarray generated in its European field trial, which exceed the targeted criteria ...

Quotient Limited Announces the Sale and Leaseback of its Edinburgh, Scotland Manufacturing and R&D Facility

JERSEY, Channel Islands, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced it has entered into definitive agreements for the sale and leaseback of its recently completed Biocampus facility located near Edinburgh, Scotland. Biocampus is a state-of-the-art facility designed to house Quotient’s rapidly growing liquid re...

Probably Relevant

BeiGene Attends Hearing Before the Listing Committee of the Stock Exchange of Hong Kong Limited

CAMBRIDGE, Mass. and BEIJING, China, July 20, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that it attended a hearing before the Listing Committee of the Stock Exchange of Hong Kong Limited (“HKEx...

Quotient Limited to Participate in the Cowen 38th Annual Global Health Care Conference

JERSEY, Channel Islands, March 01, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Cowen 38th Annual Global Health Care Conference on Tuesday, March 13th, 2018 at 8:00 a.m. EDT at The Boston Marriott Copley Place, in Boston, MA. The Compan...

20152023 World MultiWalled Carbon Nanotubes Market Research Report by Product Type, EndUser / Application and Regions / Countries [Report Updated: 01072017] Prices from USD $2800

SummaryThis report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions.Market Segment as follows:By Region / Countries North America U.S., Canada, Mexico Europe Germany, U.K., France, Italy, Russia, Spain etc South Americ...

Global and China MultiWalled Carbon Nanotubes Market Research by Company, Type Application 20132025 [Report Updated: 05032018] Prices from USD $2000

SummaryMarket Segment as follows:By Type Palm Oil Soybean Oil Sunflower Oil Rapeseed Oil Olive Oil OthersBy Application Electronic Products Semiconductor Medical Advanced Materials Aviation OthersBy Company ARKEMA S.A. HANWHA CHEMICAL CO. LTD. KUMHO PETROCHEMICAL SHOWA DENKO K.K Toray Industries CNANO TECHNOLOGY LIMITED NANOCYL S.A. HYPER...

Quotient Limited to Report Fiscal Third Quarter 2018 Financial Results and Host Conference Call

JERSEY, Channel Islands, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2017, will be released after market close on Monday, February 5, 2018. Quotient will host a conference call on Tuesday, February 6, 2018 at 8:30 a.m. Eastern Time to discuss...

Quotient Limited Updates on Status of MosaiQ Performance and Provides Third Quarter Fiscal 2018 Financial Results

Manufacturing process change implemented with improved assay performance Verification and Validation (V&V) studies for blood grouping to resumeMosaiQ SDS Microarray preparing to enter into formal V&V studiesEuropean Field Trials to commence following completion of V&V studiesConventional reagent business continues strong revenue and profitability growth JERSEY, Channel Islands...

Innovation Pharmaceuticals Views Brilacidin-OM as Clearly Differentiated Compared to Limited Competition for Preventing Severe Oral Mucositis

BEVERLY, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide shareholders with a status report on the development of Brilacidin-OM, Innovation Pharma’s novel defensin mimetic drug candidate for the prevention and treatment of Severe Oral Mucositis (SOM) in Head and Neck Canc...

Unlimited Group appoints group managing director

Michael Richards joins the group from VCCP

TMX Group Limited Declares Dividend of $0.50 per Common Share

For the results of the quarter ended December 31, 2017for TMX Group, please click on the following link: http://www.tmx.com/investor-relations/ About TMX Group (TSX:X) TMX Read more...

Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call

JERSEY, Channel Islands, May 15, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal full year ended March 31, 2018, will be released before market open on Tuesday, May 29, 2018. The Company will host a conference call to discuss its fourth quarter and fiscal full year financia...

Klox Technologies announces positive top-line results from a pivotal study of Phovia(TM) for the management of Canine Deep Pyoderma

DUBLIN, Ireland, July 02, 2018 (GLOBE NEWSWIRE) -- Klox Technologies Limited, a subsidiary of Klox Technologies Inc. ('KTI') has announced they have completed a pivotal study of Phovia for the management of Canine Deep Pyoderma. The 80-patient study met all endpoints and demonstrated that Phovia significantly reduces time to clinical resolution while reducing the durati...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks